{"classes":[{"categories":[{"measurements":[{"comment":"Median time to progression based on K-M estimate had not been reached","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to low number of events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"899.00"},{"groupId":"OG002","lowerLimit":"96.00","upperLimit":"392.00","value":"179.00"},{"groupId":"OG003","lowerLimit":"96.00","upperLimit":"392.00","value":"179.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"46"}],"units":"Participants"}],"description":"Time to progression (≥50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions) was defined as the duration from the date of the first study drug dose to the date of relapse or progression","dispersionType":"95% Confidence Interval","groups":[{"description":"Romidepsin 9mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle","id":"OG000","title":"Phase 1: Cohort 1: Romidepsin 9mg/m^2"},{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"OG001","title":"Phase 1: Cohort 2: Romidepsin 14mg/m^2"},{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"OG002","title":"Phase 2: Romidepsin 14mg/m^2"},{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"OG003","title":"Total: Romidepsin 14mg/m^2"}],"paramType":"MEDIAN","populationDescription":"ITT includes all participants who received at least one dose of romidepsin","reportingStatus":"POSTED","timeFrame":"Median follow-up time was 100 days; up to the data cut-off of 28 July 2015","title":"Kaplan Meier (K-M) Estimate of Time to Progression (TTP) in PTCL Participants Based on the Modified 2007 IWC as Assessed by IER","type":"SECONDARY","unitOfMeasure":"days"}